Source:http://linkedlifedata.com/resource/pubmed/id/11342461
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2001-5-8
|
| pubmed:abstractText |
Intractable autoimmune diseases in chimeric resistant MRL/lpr mice were treated by a new bone marrow transplantation (BMT) method consisting of fractionated irradiation, 5.5 Gy x 2, followed by intra-bone marrow (IBM) injection of whole bone marrow cells (BMCs) from allogeneic normal C57BL/6 (B6) mice (5.5 Gy x 2 + IBM). In MRL/lpr mice treated with this method, the number of donor-derived cells in the bone marrow, spleen, and liver rapidly increased (almost 100% donor-derived cells by 14 days after the treatment), and the number of donor-derived hemopoietic progenitor cells concomitantly increased. Furthermore, donor-derived stromal cells were clearly detected in the cultured bone pieces from MRL/lpr mice treated with 5.5 Gy x 2 + IBM. All the recipients thus treated survived more than 1 year (> 60 weeks after birth) and remained free from autoimmune diseases. Autoantibodies decreased to almost normal levels, and abnormal T cells (Thy1.2(+)/B220(+)/CD4(-)/CD8(-)) disappeared. Hematolymphoid cells were reconstituted with donor-derived cells, and newly developed T cells were tolerant to both donor (B6)-type and host (MRL/lpr)-type major histocompatibility complex determinants. Successful cooperation was achieved among T cells, B cells, and antigen-presenting cells when evaluated by in vitro antisheep red blood cell responses. These findings clearly indicate that this new strategy (IBM-BMT) creates the appropriate hemopoietic environment for the early recovery of hemopoiesis and donor cell engraftment, resulting in the complete amelioration of intractable autoimmune diseases in chimeric resistant MRL/lpr mice without recourse to immunosuppressants. This strategy would therefore be suitable for human therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
97
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3292-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11342461-Animals,
pubmed-meshheading:11342461-Autoantibodies,
pubmed-meshheading:11342461-Autoimmune Diseases,
pubmed-meshheading:11342461-Bone Marrow,
pubmed-meshheading:11342461-Bone Marrow Cells,
pubmed-meshheading:11342461-Bone Marrow Transplantation,
pubmed-meshheading:11342461-Cell Count,
pubmed-meshheading:11342461-Female,
pubmed-meshheading:11342461-Hematopoietic Stem Cells,
pubmed-meshheading:11342461-Injections,
pubmed-meshheading:11342461-Liver,
pubmed-meshheading:11342461-Mice,
pubmed-meshheading:11342461-Mice, Inbred BALB C,
pubmed-meshheading:11342461-Mice, Inbred C57BL,
pubmed-meshheading:11342461-Spleen,
pubmed-meshheading:11342461-Stromal Cells,
pubmed-meshheading:11342461-Survival Rate,
pubmed-meshheading:11342461-T-Lymphocytes,
pubmed-meshheading:11342461-Tissue Donors
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice.
|
| pubmed:affiliation |
First Department of Pathology, Transplantation Center, Kansai Medical University, Moriguchi City, Osaka, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|